<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD09120000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P37231</UniProt_ID>
  <Seq_Length>505</Seq_Length>
  <Molecule_Weight>57620</Molecule_Weight>
  <KEGG_ID>hsa:5468</KEGG_ID>
  <Orthology_ID>K08530</Orthology_ID>
  <EBI_ID>EBI-781384</EBI_ID>
  <Function_Summary>Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF12577:PPARgamma_N@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>5</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Nuclear receptor subfamily 1 group C member 3</Alias>
      <Alias>PPAR-gamma</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a retinoid X receptor.</Detail>
      <Keyword>Retinoid X receptor binding</Keyword>
      <Ontology_ID>GO:0046965</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).</Detail>
      <Keyword>Protein binding</Keyword>
      <Ontology_ID>GO:0005515</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a drug, any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.</Detail>
      <Keyword>Drug binding</Keyword>
      <Ontology_ID>GO:0008144</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a prostaglandin (PG) to initiate a change in cell activity.</Detail>
      <Keyword>Prostaglandin receptor activity</Keyword>
      <Ontology_ID>GO:0004955</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein that positively regulates either the transcription of one or more genes, or the translation of mRNA.</Detail>
      <Keyword>Activator</Keyword>
      <Ontology_ID>KW-0010</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with arachidonic acid, a straight chain fatty acid with 20 carbon atoms and four double bonds per molecule. Arachidonic acid is the all-Z-(5,8,11,14)-isomer.</Detail>
      <Keyword>Arachidonic acid binding</Keyword>
      <Ontology_ID>GO:0050544</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any enzyme.</Detail>
      <Keyword>Enzyme binding</Keyword>
      <Ontology_ID>GO:0019899</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an activating transcription factor, any protein whose activity is required to initiate or upregulate transcription.</Detail>
      <Keyword>Activating transcription factor binding</Keyword>
      <Ontology_ID>GO:0033613</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>A ligand-dependent receptor found in the nucleus of the cell.</Detail>
      <Keyword>Ligand-dependent nuclear receptor activity</Keyword>
      <Ontology_ID>GO:0004879</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>314</Position>
      <Original>Gln</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>316</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>388</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>113</Position>
      <Original>Pro</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>12</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>425</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>318</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>495</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>40</Position>
      <Original>Pro</Original>
      <Variation>Ala</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids, into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Lipoprotein transport</Keyword>
      <Ontology_ID>GO:0042953</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of lipid within an organism or cell.</Detail>
      <Keyword>Lipid homeostasis</Keyword>
      <Ontology_ID>GO:0055088</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.</Detail>
      <Keyword>Cellular response to insulin stimulus</Keyword>
      <Ontology_ID>GO:0032869</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A developmental process, independent of morphogenetic (shape) change, that is required for a cell to attain its fully functional state.</Detail>
      <Keyword>Cell maturation</Keyword>
      <Ontology_ID>GO:0048469</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of activity of a transcription factor, any factor involved in the initiation or regulation of transcription.</Detail>
      <Keyword>Positive regulation of transcription factor activity</Keyword>
      <Ontology_ID>GO:0051091</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of glucose within an organism or cell.</Detail>
      <Keyword>Glucose homeostasis</Keyword>
      <Ontology_ID>GO:0042593</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate or extent of cholesterol storage. Cholesterol storage is the accumulation and maintenance in cells or tissues of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Negative regulation of cholesterol storage</Keyword>
      <Ontology_ID>GO:0010887</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized myeloid precursor cell acquires the specialized features of a monocyte.</Detail>
      <Keyword>Monocyte differentiation</Keyword>
      <Ontology_ID>GO:0030224</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized cell acquires specialized features of a white adipocyte, an animal connective tissue cell involved in energy storage. White adipocytes have cytoplasmic lipids arranged in a unique vacuole.</Detail>
      <Keyword>White fat cell differentiation</Keyword>
      <Ontology_ID>GO:0050872</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of long-chain fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. A long-chain fatty acid is an aliphatic compound with a terminal carboxyl group and with a chain length greater than C12.</Detail>
      <Keyword>Long-chain fatty acid transport</Keyword>
      <Ontology_ID>GO:0015909</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin.</Detail>
      <Keyword>Placenta development</Keyword>
      <Ontology_ID>GO:0001890</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of adipocyte differentiation.</Detail>
      <Keyword>Positive regulation of fat cell differentiation</Keyword>
      <Ontology_ID>GO:0045600</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of macrophage derived foam cell differentiation. Macrophage derived foam cell differentiation is the process in which a macrophage acquires the specialized features of a foam cell. A foam cell is a type of cell containing lipids in small vacuoles and typically seen in atherosclerotic lesions, as well as other conditions.</Detail>
      <Keyword>Negative regulation of macrophage derived foam cell differentiation</Keyword>
      <Ontology_ID>GO:0010745</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency, or extent of cholesterol transporter activity.</Detail>
      <Keyword>Regulation of cholesterol transporter activity</Keyword>
      <Ontology_ID>GO:0060694</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The commitment of cells to specific cell fates and their capacity to differentiate into particular kinds of cells. Positional information is established through protein signals that emanate from a localized source within a cell (the initial one-cell zygote) or within a developmental field.</Detail>
      <Keyword>Cell fate commitment</Keyword>
      <Ontology_ID>GO:0045165</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipid stimulus.</Detail>
      <Keyword>Response to lipid</Keyword>
      <Ontology_ID>GO:0033993</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Upregulation of the activity of a caspase, any of a group of cysteine proteases involved in apoptosis.</Detail>
      <Keyword>Activation of caspase activity</Keyword>
      <Ontology_ID>GO:0006919</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure.</Detail>
      <Keyword>Regulation of blood pressure</Keyword>
      <Ontology_ID>GO:0008217</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of sequestering of triglyceride. Triglyceride sequestration is the process of binding or confining any triester of glycerol such that it is separated from other components of a biological system.</Detail>
      <Keyword>Negative regulation of sequestering of triglyceride</Keyword>
      <Ontology_ID>GO:0010891</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a low-density lipoprotein particle stimulus.</Detail>
      <Keyword>Response to low-density lipoprotein particle stimulus</Keyword>
      <Ontology_ID>GO:0055098</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized cell acquires specialized features of an epithelial cell, any of the cells making up an epithelium.</Detail>
      <Keyword>Epithelial cell differentiation</Keyword>
      <Ontology_ID>GO:0030855</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of the series of molecular events generated as a consequence of interferon-gamma binding to a cell surface receptor.</Detail>
      <Keyword>Negative regulation of interferon-gamma-mediated signaling pathway</Keyword>
      <Ontology_ID>GO:0060336</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A process that directly activates any of the steps required for cell death by apoptosis.</Detail>
      <Keyword>Induction of apoptosis</Keyword>
      <Ontology_ID>GO:0006917</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of low-density lipoprotein receptors, cell surface proteins that mediate the endocytosis of low-density lipoprotein particles by cells.</Detail>
      <Keyword>Low-density lipoprotein particle receptor biosynthetic process</Keyword>
      <Ontology_ID>GO:0045713</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the frequency or rate of receptor biosynthesis. Receptor biosynthesis is the collection of chemical reactions and pathways resulting in the formation of a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.</Detail>
      <Keyword>Negative regulation of receptor biosynthetic process</Keyword>
      <Ontology_ID>GO:0010871</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>112</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY</Protein_Seq>
    <DNA_Seq>GGCGCCCGCGCCCGCCCCCGCGCCGGGCCCGGCTCGGCCCGACCCGGCTCCGCCGCGGGCAGGCGGGGCCCAGCGCACTCGGAGCCCGAGCCCGAGCCGCAGCCGCCGCCTGGGGCGCTTGGGTCGGCCTCGAGGACACCGGAGAGGGGCGCCACGCCGCCGTGGCCGCAGAAATGACCATGGTTGACACAGAGATGCCATTCTGGCCCACCAACTTTGGGATCAGCTCCGTGGATCTCTCCGTAATGGAAGACCACTCCCACTCCTTTGATATCAAGCCCTTCACTACTGTTGACTTCTCCAGCATTTCTACTCCACATTACGAAGACATTCCATTCACAAGAACAGATCCAGTGGTTGCAGATTACAAGTATGACCTGAAACTTCAAGAGTACCAAAGTGCAATCAAAGTGGAGCCTGCATCTCCACCTTATTATTCTGAGAAGACTCAGCTCTACAATAAGCCTCATGAAGAGCCTTCCAACTCCCTCATGGCAATTGAATGTCGTGTCTGTGGAGATAAAGCTTCTGGATTTCACTATGGAGTTCATGCTTGTGAAGGATGCAAGGGTTTCTTCCGGAGAACAATCAGATTGAAGCTTATCTATGACAGATGTGATCTTAACTGTCGGATCCACAAAAAAAGTAGAAATAAATGTCAGTACTGTCGGTTTCAGAAATGCCTTGCAGTGGGGATGTCTCATAATGCCATCAGGTTTGGGCGGATGCCACAGGCCGAGAAGGAGAAGCTGTTGGCGGAGATCTCCAGTGATATCGACCAGCTGAATCCAGAGTCCGCTGACCTCCGGGCCCTGGCAAAACATTTGTATGACTCATACATAAAGTCCTTCCCGCTGACCAAAGCAAAGGCGAGGGCGATCTTGACAGGAAAGACAACAGACAAATCACCATTCGTTATCTATGACATGAATTCCTTAATGATGGGAGAAGATAAAATCAAGTTCAAACACATCACCCCCCTGCAGGAGCAGAGCAAAGAGGTGGCCATCCGCATCTTTCAGGGCTGCCAGTTTCGCTCCGTGGAGGCTGTGCAGGAGATCACAGAGTATGCCAAAAGCATTCCTGGTTTTGTAAATCTTGACTTGAACGACCAAGTAACTCTCCTCAAATATGGAGTCCACGAGATCATTTACACAATGCTGGCCTCCTTGATGAATAAAGATGGGGTTCTCATATCCGAGGGCCAAGGCTTCATGACAAGGGAGTTTCTAAAGAGCCTGCGAAAGCCTTTTGGTGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATGCACTGGAATTAGATGACAGCGACTTGGCAATATTTATTGCTGTCATTATTCTCAGTGGAGACCGCCCAGGTTTGCTGAATGTGAAGCCCATTGAAGACATTCAAGACAACCTGCTACAAGCCCTGGAGCTCCAGCTGAAGCTGAACCACCCTGAGTCCTCACAGCTGTTTGCCAAGCTGCTCCAGAAAATGACAGACCTCAGACAGATTGTCACGGAACACGTGCAGCTACTGCAGGTGATCAAGAAGACGGAGACAGACATGAGTCTTCACCCGCTCCTGCAGGAGATCTACAAGGACTTGTACTAGCAGAGAGTCCTGAGCCACTGCCAACATTTCCCTTCTTCCAGTTGCACTATTCTGAGGGAAAATCTGACACCTAAGAAATTTACTGTGAAAAAGCATTTTAAAAAGAAAAGGTTTTAGAATATGATCTATTTTATGCATATTGTTTATAAAGACACATTTACAATTTACTTTTAATATTAAAAATTACCATATTATGAAATTGCTGATAGTA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Adipose tissue</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Spleen</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Ovary</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Placenta</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>PPARG</Gene_Name>
    <Gene_Alias>NR1C3</Gene_Alias>
    <Gene_ID>5468</Gene_ID>
    <Genbank_ACCN>NM_005037</Genbank_ACCN>
    <Protein_ACCN>NP_005028</Protein_ACCN>
    <HGNC_ID>9236</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/5468</Gene_URL>
    <UCSC_ID>uc003bwr.3</UCSC_ID>
    <EMBL_ID>ENSG00000132170</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q6STE5-1</Uniprot_ID>
      <Gene_Name>SMARCD3</Gene_Name>
      <EBI_ID>EBI-488506</EBI_ID>
      <PPI_EBI_URL>EBI-781384,EBI-488506</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q00535</Uniprot_ID>
      <Gene_Name>CDK5</Gene_Name>
      <EBI_ID>EBI-1041567</EBI_ID>
      <PPI_EBI_URL>EBI-781384,EBI-1041567</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O60869</Uniprot_ID>
      <Gene_Name>EDF1</Gene_Name>
      <EBI_ID>EBI-781301</EBI_ID>
      <PPI_EBI_URL>EBI-781384,EBI-781301</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P10909</Uniprot_ID>
      <Gene_Name>CLU</Gene_Name>
      <EBI_ID>EBI-1104674</EBI_ID>
      <PPI_EBI_URL>EBI-781384,EBI-1104674</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q6STE5-2</Uniprot_ID>
      <Gene_Name>SMARCD3</Gene_Name>
      <EBI_ID>EBI-488511</EBI_ID>
      <PPI_EBI_URL>EBI-781384,EBI-488511</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Thyroid Cancer</Disease_Name>
      <Disease_Detail>Thyroid Cancer</Disease_Detail>
      <Disease_DB>THY028</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/thyroid_cancer?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Mild, Early-Onset</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_mild_early_onset?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Alcoholic Cardiomyopathy</Disease_Name>
      <Disease_Detail>Alcoholic Cardiomyopathy</Disease_Detail>
      <Disease_DB>ALC010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/alcoholic_cardiomyopathy?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pancreatic Cancer</Disease_Name>
      <Disease_Detail>Pancreatic Cancer</Disease_Detail>
      <Disease_DB>PNC035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pancreatic_cancer?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Choriocarcinoma</Disease_Name>
      <Disease_Detail>Choriocarcinoma</Disease_Detail>
      <Disease_DB>CHR074</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/choriocarcinoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Intimal Medial Thickness 1</Disease_Name>
      <Disease_Detail>Carotid Intimal Medial Thickness</Disease_Detail>
      <Disease_DB>CRT043</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_intimal_medial_thickness_1?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leptin Deficiency</Disease_Name>
      <Disease_Detail>Leptin Deficiency</Disease_Detail>
      <Disease_DB>LPT005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leptin_deficiency?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipodystrophy</Disease_Name>
      <Disease_Detail>Lipodystrophy</Disease_Detail>
      <Disease_DB>LPD010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipodystrophy?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Early-Onset</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_early_onset?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetes Mellitus, Noninsulin-Dependent, with Acanthosis Nigricans and Hypertension</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>DBT023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetes_mellitus_noninsulin_dependent_with_acanthosis_nigricans_and_hypertension?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Late-Onset</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_late_onset?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Resistance, Severe, Digenic</Disease_Name>
      <Disease_Detail>Insulin Resistance</Disease_Detail>
      <Disease_DB>INS013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_resistance_severe_digenic?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Liposarcoma</Disease_Name>
      <Disease_Detail>Liposarcoma</Disease_Detail>
      <Disease_DB>LPS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liposarcoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Variation in</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_variation_in?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Morbid Obesity</Disease_Name>
      <Disease_Detail>Morbid Obesity</Disease_Detail>
      <Disease_DB>MRB003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/morbid_obesity?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Severe, and Type Ii Diabetes</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_severe_and_type_ii_diabetes?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Autosomal Dominant</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_autosomal_dominant?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Association with</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_association_with?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Congenital Generalized Lipodystrophy Type 2</Disease_Name>
      <Disease_Detail>Congenital Generalized Lipodystrophy</Disease_Detail>
      <Disease_DB>CNG095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/congenital_generalized_lipodystrophy_type_2?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Partial Lipodystrophy</Disease_Name>
      <Disease_Detail>Familial Partial Lipodystrophy</Disease_Detail>
      <Disease_DB>FML012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_partial_lipodystrophy?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Giant Cell Glioblastoma</Disease_Name>
      <Disease_Detail>Giant Cell Glioblastoma</Disease_Detail>
      <Disease_DB>GNT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/giant_cell_glioblastoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mandibuloacral Dysplasia</Disease_Name>
      <Disease_Detail>Mandibuloacral Dysplasia</Disease_Detail>
      <Disease_DB>MND007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mandibuloacral_dysplasia?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Insulin Resistance</Disease_Name>
      <Disease_Detail>Insulin Resistance</Disease_Detail>
      <Disease_DB>INS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/insulin_resistance?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Partial Lipodystrophy Type 3</Disease_Name>
      <Disease_Detail>Familial Partial Lipodystrophy</Disease_Detail>
      <Disease_DB>FML144</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_partial_lipodystrophy_type_3?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2_diabetes_mellitus?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Salivary Gland Cancer</Disease_Name>
      <Disease_Detail>Salivary Gland Cancer</Disease_Detail>
      <Disease_DB>SLV002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/salivary_gland_cancer?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Nelson Syndrome</Disease_Name>
      <Disease_Detail>Nelson Syndrome</Disease_Detail>
      <Disease_DB>NLS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/nelson_syndrome?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retroperitoneal Liposarcoma</Disease_Name>
      <Disease_Detail>Retroperitoneal Liposarcoma</Disease_Detail>
      <Disease_DB>RTR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retroperitoneal_liposarcoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Bowenoid Papulosis</Disease_Name>
      <Disease_Detail>Bowenoid Papulosis</Disease_Detail>
      <Disease_DB>BWN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/bowenoid_papulosis?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Metabolic Syndrome X</Disease_Name>
      <Disease_Detail>Metabolic Syndrome X</Disease_Detail>
      <Disease_DB>MTB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/metabolic_syndrome_x?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retroperitoneal Sarcoma</Disease_Name>
      <Disease_Detail>Retroperitoneal Sarcoma</Disease_Detail>
      <Disease_DB>RTR010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retroperitoneal_sarcoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoatrophic Diabetes</Disease_Name>
      <Disease_Detail>Lipoatrophic Diabetes</Disease_Detail>
      <Disease_DB>LPT002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoatrophic_diabetes?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acdc</Disease_Name>
      <Disease_Detail>Acdc</Disease_Detail>
      <Disease_DB>ACD004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acdc?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carotid Intimal Medial Thickness</Disease_Name>
      <Disease_Detail>Carotid Intimal Medial Thickness</Disease_Detail>
      <Disease_DB>CRT018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carotid_intimal_medial_thickness?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity, Pparg-Related</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity_pparg_related?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acth-Secreting Pituitary Adenoma</Disease_Name>
      <Disease_Detail>Acth-Secreting Pituitary Adenoma</Disease_Detail>
      <Disease_DB>ACT010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acth_secreting_pituitary_adenoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obesity</Disease_Name>
      <Disease_Detail>Obesity</Disease_Detail>
      <Disease_DB>OBS005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obesity?search=PPARG#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gliosarcoma</Disease_Name>
      <Disease_Detail>Gliosarcoma</Disease_Detail>
      <Disease_DB>GLS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gliosarcoma?search=PPARG#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists</PDB_Title>
      <PDB_ID>2GTK</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GTK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists</PubMed_Title>
      <Author>Kuhn, B., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:4016-4020</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16737814?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-eicosatetraenoic acid</PDB_Title>
      <PDB_ID>2ZK4</PDB_ID>
      <Resolution>2.57</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>J.Mol.Biol.(2009)385:188-199</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Acid and NCOA2 Peptide</PDB_Title>
      <PDB_ID>3DZU</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DZU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.</PubMed_Title>
      <Author>Chandra, V., et al.</Author>
      <Journal>Nature(2008)456:350-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19043829?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of PPARgamma ligand binding domain in complex with (R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione</PDB_Title>
      <PDB_ID>3TY0</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TY0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Benzimidazolones - A New Class of Selective Peroxisome Proliferator-Activated Receptor Gamma (PPARg) Modulators.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutathion conjugated 15-deoxy-delta12,14-prostaglandin J2</PDB_Title>
      <PDB_ID>2ZK2</PDB_ID>
      <Resolution>2.26</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>J.Mol.Biol.(2009)385:188-199</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2</PDB_Title>
      <PDB_ID>2ZVT</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZVT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Febs Lett.(2009)583:320-324</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19101554?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-eicosatetraenoic acid</PDB_Title>
      <PDB_ID>2ZK3</PDB_ID>
      <Resolution>2.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>J.Mol.Biol.(2009)385:188-199</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Acid and NCOA2 Peptide</PDB_Title>
      <PDB_ID>3E00</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E00</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.</PubMed_Title>
      <Author>Chandra, V., et al.</Author>
      <Journal>Nature(2008)456:350-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19043829?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARg in complex with INT131</PDB_Title>
      <PDB_ID>3FUR</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FUR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>INT131: a selective modulator of PPAR gamma</PubMed_Title>
      <Author>Motani, A., et al.</Author>
      <Journal>J.Mol.Biol.(2009)386:1301-1311</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19452630?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue)</PDB_Title>
      <PDB_ID>3CDS</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CDS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) Ligand Binding Domain Complexed with a Novel Partial Agonist: A New Region of the Hydrophobic Pocket Could Be Exploited for Drug Design</PubMed_Title>
      <Author>Montanari, R., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:7768-7776</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19053776?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator</PDB_Title>
      <PDB_ID>3LMP</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3LMP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives</PubMed_Title>
      <Author>Furukawa, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2010)20:2095-2098</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20219371?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-233</PDB_Title>
      <PDB_ID>2ZK5</PDB_ID>
      <Resolution>2.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>J.Mol.Biol.(2009)385:188-199</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Revealing a steroid receptor ligand as a unique PPARgamma agonist</PDB_Title>
      <PDB_ID>3QT0</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3QT0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Revealing a steroid receptor ligand as a unique PPARgamma agonist</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R</PDB_Title>
      <PDB_ID>3AN4</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3AN4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, Synthesis, and Structural Analysis of Phenylpropanoic Acid-Type PPAR gamma-Selective Agonists: Discovery of Reversed Stereochemistry-Activity Relationship</PubMed_Title>
      <Author>Ohashi, M., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:331-341</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21128600?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex between PPARgamma and the agonist LT160 (ureidofibrate derivative)</PDB_Title>
      <PDB_ID>2I4J</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I4J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands</PubMed_Title>
      <Author>Pochetti, G., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:17314-17324</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17403688?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPARgamma ligand-binding domain in complex with indomethacin</PDB_Title>
      <PDB_ID>3ADS</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ADS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by SHP</PDB_Title>
      <PDB_ID>1ZGY</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZGY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner.</PubMed_Title>
      <Author>Li, Y., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2005)102:9505-9510</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15976031?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray crystallography and in vitro/in vivo biological activities</PDB_Title>
      <PDB_ID>2G0G</PDB_ID>
      <Resolution>2.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G0G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-Based Drug Design of a Novel Family of PPARgamma Partial Agonists: Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities</PubMed_Title>
      <Author>Lu, I.L., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:2703-2712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16640330?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233</PDB_Title>
      <PDB_ID>3ADX</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ADX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator</PDB_Title>
      <PDB_ID>3V9T</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V9T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPAR(gamma) partial agonists</PubMed_Title>
      <Author>Furukawa, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:1348-1351</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22225641?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S</PDB_Title>
      <PDB_ID>3AN3</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3AN3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, Synthesis, and Structural Analysis of Phenylpropanoic Acid-Type PPAR gamma-Selective Agonists: Discovery of Reversed Stereochemistry-Activity Relationship</PubMed_Title>
      <Author>Ohashi, M., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:331-341</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21128600?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). Structure obtained from crystals of the apo-form soaked for 30 days.</PDB_Title>
      <PDB_ID>2I4P</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I4P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.</PubMed_Title>
      <Author>Pochetti, G., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:17314-17324</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17403688?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Cerco-A</PDB_Title>
      <PDB_ID>3B1M</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B1M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Pharmacology and in Vitro Profiling of a Novel Peroxisome Proliferator-Activated Receptor gamma Ligand, Cerco-A</PubMed_Title>
      <Author>Wakabayashi, K., et al.</Author>
      <Journal>Biol.Pharm.Bull.(2011)34:1094-1104</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21720019?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with 4-HDHA</PDB_Title>
      <PDB_ID>2VV1</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VV1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Pparg by Oxidised Fatty Acids</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural and Biochemical Basis for the Binding Selectivity of PPARg to PGC-1a</PDB_Title>
      <PDB_ID>3CS8</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CS8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor gamma to PGC-1alpha.</PubMed_Title>
      <Author>Li, Y., et al.</Author>
      <Journal>J.Biol.Chem.(2008)283:19132-19139</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18469005?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist</PDB_Title>
      <PDB_ID>3H0A</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H0A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.</PubMed_Title>
      <Author>Connors, R.V., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:3550-3554</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19464171?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2</PDB_Title>
      <PDB_ID>2ZK1</PDB_ID>
      <Resolution>2.61</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>J.Mol.Biol.(2009)385:188-199</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARgamma bound to partial agonist nTZDpa</PDB_Title>
      <PDB_ID>2Q5S</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q5S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism</PubMed_Title>
      <Author>Bruning, J.B., et al.</Author>
      <Journal>Structure(2007)15:1258-1271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17937915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate</PDB_Title>
      <PDB_ID>3ADT</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ADT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARg in complex with T2384</PDB_Title>
      <PDB_ID>3K8S</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3K8S</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD09120003</ASD_Ligand>
      <PubMed_Title>T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties</PubMed_Title>
      <Author>Li, Y., et al.</Author>
      <Journal>J.Biol.Chem.(2008)283:9168-9176</Journal>
      <PubMed_ID>18263587</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with an Alpha-Aryloxyphenylacetic Acid Agonist</PDB_Title>
      <PDB_ID>1ZEO</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZEO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Synthesis of alpha-Aryloxyphenylacetic Acid Derivatives: A Novel Class of PPAR alpha/gamma Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity</PubMed_Title>
      <Author>Shi, G.Q., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:4457-4468</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15974597?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid</PDB_Title>
      <PDB_ID>3CDP</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CDP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structures of PPARgamma ligand binding domain complexed with new partial and full agonists: a new region of the hydrophobic pocket could be exploited for drug design</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex between PPARgamma and the full agonist LT175</PDB_Title>
      <PDB_ID>3B3K</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B3K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) Ligand Binding Domain Complexed with a Novel Partial Agonist: A New Region of the Hydrophobic Pocket Could Be Exploited for Drug Design</PubMed_Title>
      <Author>Montanari, R., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:7768-7776</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19053776?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARgamma complexed with Telmisartan</PDB_Title>
      <PDB_ID>3VN2</PDB_ID>
      <Resolution>2.18</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3VN2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for telmisartan-mediated partial activation of PPAR gamma</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>High Resolution Structure of Peroxisone Proliferation-Activated Receptor gamma and Characterisation of its Interaction with the Co-activator Transcriptional Intermediary Factor 2</PDB_Title>
      <PDB_ID>2QMV</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QMV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High Resolution Structure of Peroxisone Proliferation-Activated Receptor gamma and Characterisation of its Interaction with the Co-activator Transcriptional Intermediary Factor 2</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid</PDB_Title>
      <PDB_ID>3SZ1</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3SZ1</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mode of PPARgamma Activation by Luteolin.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides</PDB_Title>
      <PDB_ID>2Q6S</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q6S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism</PubMed_Title>
      <Author>Bruning, J.B., et al.</Author>
      <Journal>Structure(2007)15:1258-1271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17937915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPAR gamma complexed with partial agonist SF147</PDB_Title>
      <PDB_ID>2Q6R</PDB_ID>
      <Resolution>2.41</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q6R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism</PubMed_Title>
      <Author>Bruning, J.B., et al.</Author>
      <Journal>Structure(2007)15:1258-1271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17937915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA</PDB_Title>
      <PDB_ID>2PRG</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PRG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.</PubMed_Title>
      <Author>Nolte, R.T., et al.</Author>
      <Journal>Nature(1998)395:137-143</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9744270?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPAR gamma ligand binding domain in complex with MCC555</PDB_Title>
      <PDB_ID>3B0Q</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B0Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human PPAR gamma in complex with MCC555</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Ligand binding domain of PPARgamma complexed with Decanoic Acid and PGC-1a peptide</PDB_Title>
      <PDB_ID>3U9Q</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3U9Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification and Mechanism of 10-Carbon Fatty Acid as Modulating Ligand of Peroxisome Proliferator-activated Receptors.</PubMed_Title>
      <Author>Malapaka, R.R., et al.</Author>
      <Journal>J.Biol.Chem.(2012)287:183-195</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22039047?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes</PDB_Title>
      <PDB_ID>3G9E</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G9E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.</PubMed_Title>
      <Author>Benardeau, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:2468-2473</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19349176?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate</PDB_Title>
      <PDB_ID>3ADU</PDB_ID>
      <Resolution>2.77</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ADU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator</PDB_Title>
      <PDB_ID>3V9Y</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V9Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPAR(gamma) partial agonists</PubMed_Title>
      <Author>Furukawa, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2012)22:1348-1351</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22225641?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145</PDB_Title>
      <PDB_ID>2Q61</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q61</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism</PubMed_Title>
      <Author>Bruning, J.B., et al.</Author>
      <Journal>Structure(2007)15:1258-1271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17937915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). This structure has been obtained from crystals soaked for 6 hours.</PDB_Title>
      <PDB_ID>2I4Z</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2I4Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands</PubMed_Title>
      <Author>Pochetti, G., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:17314-17324</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17403688?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound with dual PPAR gamma agonism and Angiotensin II Type I receptor antagonism activity</PDB_Title>
      <PDB_ID>3R8A</PDB_ID>
      <Resolution>2.41</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R8A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of a Series of Imidazo[4,5-b]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-gamma.</PubMed_Title>
      <Author>Casimiro-Garcia, A., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:4219-4233</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21557540?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retinoic Acid and NCOA2 Peptide</PDB_Title>
      <PDB_ID>3DZY</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DZY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.</PubMed_Title>
      <Author>Chandra, V., et al.</Author>
      <Journal>Nature(2008)456:350-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19043829?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPARgamma heterodimer</PDB_Title>
      <PDB_ID>1RDT</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RDT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of potent retinoid X receptor alpha agonists.</PubMed_Title>
      <Author>Haffner, C.D., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:2010-2029</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15056000?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain</PDB_Title>
      <PDB_ID>2ZK0</PDB_ID>
      <Resolution>2.36</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>J.Mol.Biol.(2009)385:188-199</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18977231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with DHA</PDB_Title>
      <PDB_ID>2VV0</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VV0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Pparg by Oxidised Fatty Acids</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPRR gamma ligand binding domain in complex with a synthetic agonist TIPP703</PDB_Title>
      <PDB_ID>2ZNO</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZNO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures</PubMed_Title>
      <Author>Oyama, T., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2009)65:786-795</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19622862?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARgamma LBD bound to full agonist MRL20</PDB_Title>
      <PDB_ID>2Q59</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q59</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD09128001</ASD_Ligand>
      <PubMed_Title>Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism</PubMed_Title>
      <Author>Bruning, J.B., et al.</Author>
      <Journal>Structure(2007)15:1258-1271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17937915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist</PDB_Title>
      <PDB_ID>2Q8S</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q8S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.</PubMed_Title>
      <Author>Casimiro-Garcia, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2008)16:4883-4907</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18394907?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of human ppar gamma with 2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2h-1,2,3-triazol-4-yl)acetic acid</PDB_Title>
      <PDB_ID>3BC5</PDB_ID>
      <Resolution>2.27</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BC5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:1451-1456</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19201606?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPARgamma ligand-binding domain in complex with serotonin</PDB_Title>
      <PDB_ID>3ADV</PDB_ID>
      <Resolution>2.27</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ADV</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, and an SRC-1 Peptide</PDB_Title>
      <PDB_ID>3KMG</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KMG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and biological activities of novel indole derivatives as potent and selective PPAR-gamma modulators</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with a Potent and Selective Agonist</PDB_Title>
      <PDB_ID>3GBK</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GBK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists</PubMed_Title>
      <Author>Lin, C.-H., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:2618-2622</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19301897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray crystallography and in vitro/in vivo biological activities</PDB_Title>
      <PDB_ID>2G0H</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G0H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-Based Drug Design of a Novel Family of PPARgamma Partial Agonists: Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities</PubMed_Title>
      <Author>Lu, I.L., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:2703-2712</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16640330?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPAR Gamma with N-sulfonyl-2-indole carboxamide ligands</PDB_Title>
      <PDB_ID>2HFP</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HFP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis.</PubMed_Title>
      <Author>Hopkins, C.R., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2006)16:5659-5663</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16919947?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid</PDB_Title>
      <PDB_ID>3HO0</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HO0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors alpha/gamma Dual Agonists with Improved Potency and Reduced Adverse Effects on Skeletal Muscle Function</PubMed_Title>
      <Author>Fracchiolla, G., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:6382-6393</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19775169?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Molecular recognition of nitro-fatty acids by PPAR gamma</PDB_Title>
      <PDB_ID>3CWD</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CWD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular recognition of nitrated fatty acids by PPAR gamma.</PubMed_Title>
      <Author>Li, Y., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:865-867</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18604218?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid</PDB_Title>
      <PDB_ID>3ET3</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ET3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</PubMed_Title>
      <Author>Artis, D.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:262-267</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19116277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator</PDB_Title>
      <PDB_ID>3V9V</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V9V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPAR(gamma) partial agonists</PubMed_Title>
      <Author>Furukawa, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2011)22:1348-1351</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22225641?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Design and biological evaluation of novel, balanced dual PPARa/g agonists</PDB_Title>
      <PDB_ID>3FEJ</PDB_ID>
      <Resolution>2.01</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FEJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists</PubMed_Title>
      <Author>Grether, U., et al.</Author>
      <Journal>Chemmedchem(2009)4:951-956</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19326383?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR</PDB_Title>
      <PDB_ID>3PRG</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PRG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma.</PubMed_Title>
      <Author>Uppenberg, J., et al.</Author>
      <Journal>J.Biol.Chem.(1998)273:31108-31112</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9813012?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid</PDB_Title>
      <PDB_ID>3ET0</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ET0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent</PubMed_Title>
      <Author>Artis, D.R., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2009)106:262-267</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19116277?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.</PDB_Title>
      <PDB_ID>1FM9</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FM9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.</PubMed_Title>
      <Author>Gampe Jr., R.T., et al.</Author>
      <Journal>Mol.Cell(2000)5:545-555</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10882139?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86)</PDB_Title>
      <PDB_ID>3R8I</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R8I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.</PubMed_Title>
      <Author>Porcelli, L., et al.</Author>
      <Journal>J.Med.Chem.(2012)55:37-54</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22081932?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid</PDB_Title>
      <PDB_ID>3HOD</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HOD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors alpha/gamma Dual Agonists with Improved Potency and Reduced Adverse Effects on Skeletal Muscle Function</PubMed_Title>
      <Author>Fracchiolla, G., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:6382-6393</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19775169?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of PPARgamma bound to partial agonist MRL24</PDB_Title>
      <PDB_ID>2Q5P</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q5P</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD09128002</ASD_Ligand>
      <PubMed_Title>Partial Agonists Activate PPARgamma Using a Helix 12 Independent Mechanism</PubMed_Title>
      <Author>Bruning, J.B., et al.</Author>
      <Journal>Structure(2007)15:1258-1271</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17937915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with 13-(S)-HODE</PDB_Title>
      <PDB_ID>2VST</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VST</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Pparg by Oxidised Fatty Acids</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator</PDB_Title>
      <PDB_ID>2P4Y</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2P4Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.</PubMed_Title>
      <Author>Einstein, M., et al.</Author>
      <Journal>Mol.Pharmacol.(2008)73:62-74</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17940191?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA)</PDB_Title>
      <PDB_ID>3OSW</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OSW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Peroxysome Proliferator-Activated Receptor Gamma is a Target for Halogenated Analogues of Bisphenol-A.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242</PDB_Title>
      <PDB_ID>1I7I</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1I7I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.</PubMed_Title>
      <Author>Cronet, P., et al.</Author>
      <Journal>Structure(2001)9:699-701</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11587644?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro</PDB_Title>
      <PDB_ID>2FVJ</PDB_ID>
      <Resolution>1.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FVJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro</PubMed_Title>
      <Author>Burgermeister, E., et al.</Author>
      <Journal>Mol.Endocrinol.(2006)20:809-830</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16373399?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist</PDB_Title>
      <PDB_ID>2F4B</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F4B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Indol-1-yl Acetic Acids as Peroxisome Proliferator-Activated Receptor Agonists: Design, Synthesis, Structural Biology, and Molecular Docking Studies</PubMed_Title>
      <Author>Mahindroo, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:1212-1216</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16451087?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatetraenoic acid</PDB_Title>
      <PDB_ID>3ADW</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ADW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with 4-oxoDHA</PDB_Title>
      <PDB_ID>2VV3</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VV3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Ppargamma by Oxidized Fatty Acids.</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalpha ligand binding domains respectively bound with GW409544 and 9-cis retinoic acid and co-activator peptides.</PDB_Title>
      <PDB_ID>1K74</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K74</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.</PubMed_Title>
      <Author>Xu, H.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2001)98:13919-13924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11698662?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma</PDB_Title>
      <PDB_ID>2OM9</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OM9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Ajulemic Acid, a Synthetic Nonpsychoactive Cannabinoid Acid, Bound to the Ligand Binding Domain of the Human Peroxisome Proliferator-activated Receptor gamma</PubMed_Title>
      <Author>Ambrosio, A.L.B., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:18625-18633</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17462987?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human PPAR gamma ligand binding dmain complexed with GW9662 in a covalent bonded form</PDB_Title>
      <PDB_ID>3B0R</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B0R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human PPAR gamma ligand binding dmain complexed with GW9662 in a covalent bonded form</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer)</PDB_Title>
      <PDB_ID>3D6D</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D6D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) Ligand Binding Domain Complexed with a Novel Partial Agonist: A New Region of the Hydrophobic Pocket Could Be Exploited for Drug Design</PubMed_Title>
      <Author>Montanari, R., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:7768-7776</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19053776?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol A (MonoTBBPA)</PDB_Title>
      <PDB_ID>3PBA</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PBA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Characterization of Novel Ligands of ER{alpha}, Er{beta}, and PPAR{gamma}: The Case of Halogenated Bisphenol A and Their Conjugated Metabolites.</PubMed_Title>
      <Author>Riu, A., et al.</Author>
      <Journal>Toxicol Sci(2011)122:372-382</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21622942?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PPARgamma Ligand binding domain complexed with a farglitazar analogue gw4709</PDB_Title>
      <PDB_ID>2POB</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2POB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Cocrystal structure guided array synthesis of PPARgamma inverse agonists</PubMed_Title>
      <Author>Trump, R.P., et al.</Author>
      <Journal>BIOORG.MED.CHEM.LETT.(2007)17:3916-3920</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17533125?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST</PDB_Title>
      <PDB_ID>1KNU</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KNU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity</PubMed_Title>
      <Author>Sauerberg, P., et al.</Author>
      <Journal>J.MED.CHEM.(2002)45:789-804</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11831892?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.</PDB_Title>
      <PDB_ID>1FM6</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FM6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.</PubMed_Title>
      <Author>Gampe Jr., R.T., et al.</Author>
      <Journal>Mol.Cell(2000)5:545-555</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10882139?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist</PDB_Title>
      <PDB_ID>3IA6</PDB_ID>
      <Resolution>2.31</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IA6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.</PubMed_Title>
      <Author>Casimiro-Garcia, A., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2009)17:7113-7125</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19783444?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with 6-oxoOTE</PDB_Title>
      <PDB_ID>2VV4</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VV4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Pparg by Oxidised Fatty Acids</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPARgammaLBD complexed with the agonist magnolol</PDB_Title>
      <PDB_ID>3R5N</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R5N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular determinants of magnolol targeting both RXR(alpha) and PPAR(gamma).</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>Plos One(2011)6:e28253-e28253</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22140563?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PPARgamma in complex with a 2-BABA compound</PDB_Title>
      <PDB_ID>1WM0</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1WM0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects</PubMed_Title>
      <Author>Ostberg, T., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:41124-41130</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15258145?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the ligand binding domain of human PPAR-gamma im complex with an agonist</PDB_Title>
      <PDB_ID>2ATH</PDB_ID>
      <Resolution>2.28</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ATH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities</PubMed_Title>
      <Author>Mahindroo, N., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:8194-8208</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16366601?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with an agonist</PDB_Title>
      <PDB_ID>1NYX</PDB_ID>
      <Resolution>2.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1NYX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar</PubMed_Title>
      <Author>Ebdrup, S., et al.</Author>
      <Journal>J.MED.CHEM.(2003)46:1306-1317</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12672231?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL</PDB_Title>
      <PDB_ID>4PRG</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4PRG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.</PubMed_Title>
      <Author>Oberfield, J.L., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1999)96:6102-6106</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10339548?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists</PDB_Title>
      <PDB_ID>2HWQ</PDB_ID>
      <Resolution>1.97</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HWQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists</PubMed_Title>
      <Author>Mahindroo, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:6421-6424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17034149?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with 5-HEPA</PDB_Title>
      <PDB_ID>2VV2</PDB_ID>
      <Resolution>2.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VV2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Pparg by Oxidised Fatty Acids</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists</PDB_Title>
      <PDB_ID>2HWR</PDB_ID>
      <Resolution>2.34</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HWR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists</PubMed_Title>
      <Author>Mahindroo, N., et al.</Author>
      <Journal>J.Med.Chem.(2006)49:6421-6424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17034149?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA</PDB_Title>
      <PDB_ID>1PRG</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PRG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.</PubMed_Title>
      <Author>Nolte, R.T., et al.</Author>
      <Journal>Nature(1998)395:137-143</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9744270?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA)</PDB_Title>
      <PDB_ID>3OSI</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OSI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Peroxysome Proliferator-Activated Receptor Gamma is a Target for Halogenated Analogues of Bisphenol-A.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>hPPARgamma Ligand binding domain in complex with 9-(S)-HODE</PDB_Title>
      <PDB_ID>2VSR</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VSR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Activation of Pparg by Oxidised Fatty Acids</PubMed_Title>
      <Author>Itoh, T., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2008)15:924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19172745?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE</PDB_Title>
      <PDB_ID>2XKW</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2XKW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Binding Diversity of Pioglitazone by Peroxisome Proliferator-Activated Receptor-Gamma</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODIPY</PDB_Title>
      <PDB_ID>2ZK6</PDB_ID>
      <Resolution>2.41</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZK6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites</PubMed_Title>
      <Author>Waku, T., et al.</Author>
      <Journal>Embo J.(2010)29:3395-3407</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20717101?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin</PDB_Title>
      <PDB_ID>3PO9</PDB_ID>
      <Resolution>2.35</Resolution>
      <Has_Ligand>No</Has_Ligand>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human PPAR-gamma ligand binding domain complex with a potency improved agonist</PDB_Title>
      <PDB_ID>3NOA</PDB_ID>
      <Resolution>1.98</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NOA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human PPAR-gamma ligand binding domain complex with a potency improved agonist</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05216</Pathway_ID>
      <Pathway_Title>Thyroid cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05216</Pathway_ID>
      <Pathway_Title>Thyroid cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04152</Pathway_ID>
      <Pathway_Title>AMPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04380</Pathway_ID>
      <Pathway_Title>Osteoclast differentiation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Development</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05016</Pathway_ID>
      <Pathway_Title>Huntington's disease</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Neurodegenerative diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.bh.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1fm6</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD09120001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09120002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09120003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09128001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09128002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>